Paradromics Inc., a company focused on neurotechnology, has successfully carried out its first human procedure involving a Brain-Computer Interface (BCI) following almost three years of preclinical studies. This procedure was executed under the direction of Dr. Matthew Wilsey from the University of Michigan, alongside a team of clinicians and engineers. The Connexus BCI aims to create direct communication routes between the brain and external devices.
The device was implanted during a surgery meant to address epilepsy, specifically while removing the section of the brain responsible for seizures. The operation demonstrated how effectively the device could record electrical brain signals, achieving this within just 20 minutes.
With this initial success, Paradromics marks an important milestone in its clinical endeavors, stepping into a competitive landscape alongside companies like Neuralink, Synchron, and Precision Neuroscience.
As of April, there were already three patients undergoing trials with Neuralink’s brain implants. Matt Angle, the CEO of Paradromics, founded the company in 2015, envisioning a BCI that could handle high data rates, thus opening new avenues for brain health applications.
The Connexus devices are engineered to help individuals suffering from severe motor disorders, such as those resulting from amyotrophic lateral sclerosis (ALS), brainstem strokes, or spinal cord injuries. This platform employs artificial intelligence to turn brain signals into actionable outputs, aiming for communication that feels natural and mimics complex tasks like using a mouse or keyboard.
Looking ahead, the company plans to initiate clinical trials later this year to evaluate the long-term effects and safety of the Connexus BCI, pending regulatory approval.
